Kawasaki disease - Revision history

Danbot: Add peer-reviewed reference

2026-03-22T10:16:01Z

Add peer-reviewed reference

← Older revision		Revision as of 10:16, 22 March 2026
Line 1:		Line 1:
	==Background==		==Background==
	*Also known as: mucocutaneous lymph node syndrome		*Also known as: mucocutaneous lymph node syndrome<ref>McCrindle BW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the AHA. Circulation. 2017;135(17):e927-e999. PMID 28356445</ref>
	*[[Vasculitis]] of unknown etiology		*[[Vasculitis]] of unknown etiology
	**Likely a combination of genetic, infectious, and regional factors		**Likely a combination of genetic, infectious, and regional factors

Danbot: Add MedicationDose SMW entries for IVIG and aspirin; doses verified against AHA Kawasaki disease guidelines

2026-03-20T18:02:42Z

Add MedicationDose SMW entries for IVIG and aspirin; doses verified against AHA Kawasaki disease guidelines

← Older revision		Revision as of 18:02, 20 March 2026
Line 163:		Line 163:
	*Admit		*Admit
	*Follow-up cardiac evaluation for coronary aneurysm screening		*Follow-up cardiac evaluation for coronary aneurysm screening


			==Medication Dosing==
			*{{MedicationDose\|drug=IVIG\|dose=2 g/kg over 12hr\|route=IV\|context=Primary treatment\|indication=Kawasaki disease\|population=Pediatric\|notes=Requires inpatient monitoring for allergic reaction}}
			*{{MedicationDose\|drug=Aspirin\|dose=30-100 mg/kg/day divided QID (acute), then 3-5 mg/kg/day (antiplatelet)\|route=PO\|context=Anti-inflammatory/antiplatelet\|indication=Kawasaki disease\|population=Pediatric\|notes=Has not been shown to prevent coronary aneurysms; Reye syndrome not reported with KD treatment}}

	==See Also==		==See Also==

Moomoodoctor: /* Management */

2024-05-03T16:03:48Z

Management

← Older revision		Revision as of 16:03, 3 May 2024
Line 151:		Line 151:
	**May increase ESR as IGs are positively charged which increases RBC sedimentation[1]		**May increase ESR as IGs are positively charged which increases RBC sedimentation[1]
	*[[Aspirin]]		*[[Aspirin]]
	**30-100mg/kg/day is often used		**30-100mg/kg/day divided 4 times a day is often used
	**Has not been shown to prevent coronary artery aneurysms		**Has not been shown to prevent coronary artery aneurysms
	**3-5mg/kg/day is appropriate for anti-platelet activity		**3-5mg/kg/day is appropriate for anti-platelet activity
Line 158:		Line 158:
	**For high-risk patients		**For high-risk patients
	**Decreases CAA formation if started with IVIG		**Decreases CAA formation if started with IVIG
	**Using as a rescue for IVIG resistant patients is less effective		**Using it as a rescue for IVIG-resistant patients is less effective

	==Disposition==		==Disposition==

Moomoodoctor: /* Management */

2024-05-03T15:58:55Z

Management

← Older revision		Revision as of 15:58, 3 May 2024
Line 106:		Line 106:
	Assess risk for IVIG resistance (There are 4 scoring systems):		Assess risk for IVIG resistance (There are 4 scoring systems):
	{\| class="wikitable"		{\| class="wikitable"
	! Scoring System !! Nation !! Enrolled ~~Patients~~ !! IVIG ~~Resistance~~ !! Sensitivity !! Specificity !! Risk Factors !! Point !! Predicted ~~Risk~~ (score) !!		! Scoring System !! Nation !! Enrolled patients !! IVIG resistance !! Sensitivity !! Specificity !! Risk Factors !! Point !! Predicted risk (score)
	\|-		\|-
	\| Egami \|\| Japan \|\| 320 \|\| 41 \|\| 78 \|\| 76 \|\| Age <6 Mo \|\| 1 \|\| Low ~~Risk~~ (0-2) \|\|		\| Egami \|\| Japan \|\| 320 \|\| 41 \|\| 78 \|\| 76 \|\| Age <6 mo \|\| 1 \|\| Low risk (0-2)
	\|-		\|-
	\| \|\| \|\| \|\| \|\| \|\| \|\| Illness <4 ~~Days~~ \|\| 1 \|\| \|\|		\| \|\| \|\| \|\| \|\| \|\| \|\| Illness <4 days \|\| 1 \|\|
	\|-		\|-
	\| \|\| \|\| \|\| \|\| \|\| \|\| CRP 8+ Mg/dL \|\| 1 \|\| High ~~Risk~~ (3+) \|\|		\| \|\| \|\| \|\| \|\| \|\| \|\| CRP 8+ mg/dL \|\| 1 \|\| High risk (3+)
	\|-		\|-
	\| \|\| \|\| \|\| \|\| \|\| \|\| ALT 80+ Mg/dL \|\| 2 \|\| \|\|		\| \|\| \|\| \|\| \|\| \|\| \|\| ALT 80+ mg/dL \|\| 2 \|\|
	\|-		\|-
	\| \|\| \|\| \|\| \|\| \|\| \|\| Platelets < 300 \|\| 1 \|\| \|\|		\| \|\| \|\| \|\| \|\| \|\| \|\| Platelets < 300 \|\| 1 \|\|
	\|-		\|-
	\| Kobayashi \|\| Japan \|\| 528 \|\| 148 \|\| 86 \|\| 68 \|\| Age <12 Mo \|\| 1 \|\| Low ~~Risk~~ (0-3) \|\|		\| Kobayashi \|\| Japan \|\| 528 \|\| 148 \|\| 86 \|\| 68 \|\| Age <12 mo \|\| 1 \|\| Low risk (0-3)
	\|-		\|-
	\| \|\| \|\| \|\| \|\| \|\| \|\| Illness ~~Days~~ <4 ~~Days~~ \|\| 2 \|\| \|\|		\| \|\| \|\| \|\| \|\| \|\| \|\| Illness days <4 days \|\| 2 \|\|
	\|-		\|-
	\| \|\| \|\| \|\| \|\| \|\| \|\| CRP >10 Mg/dL \|\| 1 \|\| High ~~Risk~~ (4+) \|\|		\| \|\| \|\| \|\| \|\| \|\| \|\| CRP >10 mg/dL \|\| 1 \|\| High risk (4+)
	\|-		\|-
	\| \|\| \|\| \|\| \|\| \|\| \|\| ALT >100 Mg/dL \|\| 2 \|\| \|\|		\| \|\| \|\| \|\| \|\| \|\| \|\| ALT >100 mg/dL \|\| 2 \|\|
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| Platelets < 300 \|\| 1 \|\|
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| Na <133 \|\| 2 \|\|
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| Neutrophils >80% \|\| 2 \|\|
			\|-
			\| San Diego \|\| US \|\| 362 \|\| 60 \|\| 73.3 \|\| 61.9 \|\| Illness <4 days \|\| 1 \|\| Low risk (0-1)
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| GGT 60+ IU/L \|\| 1 \|\|
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| zHgb < -2 \|\| 1 \|\| High risk (2+)
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| Bands >20 \|\| 2 \|\|
			\|-
			\| Formosa \|\| Taiwan \|\| 248 \|\| 29 \|\| 86.2 \|\| 81.3 \|\| Lymphadenopathy \|\| 1 \|\| Low risk (0-2)
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| Neutrophils >60% \|\| 2 \|\| High risk (3+)
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| Albumin <3.5g/dL \|\| 1 \|\|
	\|}		\|}


	*[[IVIG]] 2gm/kg over 12hr		*[[IVIG]] 2gm/kg over 12hr

Moomoodoctor: /* Management */

2024-05-03T15:55:42Z

Management

← Older revision		Revision as of 15:55, 3 May 2024
Line 104:		Line 104:

	==Management==		==Management==
	Assess risk for IVIG resistance:		Assess risk for IVIG resistance (There are 4 scoring systems):
	Scoring System Nation Enrolled Patients IVIG Resistance Sensitivity Specificity Risk Factors Point Predicted Risk (score)		{\| class="wikitable"
	Egami Japan 320 41 78 76 Age <6 Mo 1 Low Risk (0-2)		! Scoring System !! Nation !! Enrolled Patients !! IVIG Resistance !! Sensitivity !! Specificity !! Risk Factors !! Point !! Predicted Risk (score) !!
	Illness <4 Days 1		\|-
	CRP 8+ Mg/dL 1 High Risk (3+)		\| Egami \|\| Japan \|\| 320 \|\| 41 \|\| 78 \|\| 76 \|\| Age <6 Mo \|\| 1 \|\| Low Risk (0-2) \|\|
	ALT 80+ Mg/dL 2		\|-
	Platelets < 300 1		\| \|\| \|\| \|\| \|\| \|\| \|\| Illness <4 Days \|\| 1 \|\| \|\|
	Kobayashi Japan 528 148 86 68 Age <12 Mo 1 Low Risk (0-3)		\|-
	Illness Days <4 Days 2		\| \|\| \|\| \|\| \|\| \|\| \|\| CRP 8+ Mg/dL \|\| 1 \|\| High Risk (3+) \|\|
	CRP >10 Mg/dL 1 High Risk (4+)		\|-
	ALT >100 Mg/dL 2		\| \|\| \|\| \|\| \|\| \|\| \|\| ALT 80+ Mg/dL \|\| 2 \|\| \|\|
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| Platelets < 300 \|\| 1 \|\| \|\|
			\|-
			\| Kobayashi \|\| Japan \|\| 528 \|\| 148 \|\| 86 \|\| 68 \|\| Age <12 Mo \|\| 1 \|\| Low Risk (0-3) \|\|
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| Illness Days <4 Days \|\| 2 \|\| \|\|
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| CRP >10 Mg/dL \|\| 1 \|\| High Risk (4+) \|\|
			\|-
			\| \|\| \|\| \|\| \|\| \|\| \|\| ALT >100 Mg/dL \|\| 2 \|\| \|\|
			\|}

Moomoodoctor: /* Management */

2024-05-03T15:53:45Z

Management

@@ Line 104: / Line 104: @@
 ==Management==
 *[[IVIG]] 2gm/kg over 12hr
 **Requires inpatient monitoring for allergic reaction

Moomoodoctor: /* Management */

2024-05-02T22:12:28Z

Management

← Older revision		Revision as of 22:12, 2 May 2024
Line 112:		Line 112:
	**3-5mg/kg/day is appropriate for anti-platelet activity		**3-5mg/kg/day is appropriate for anti-platelet activity
	**[[Reye Syndrome]] has not been reported in association with KD treatment with aspirin		**[[Reye Syndrome]] has not been reported in association with KD treatment with aspirin
			*[[Steroids]]
			**For high-risk patients
			**Decreases CAA formation if started with IVIG
			**Using as a rescue for IVIG resistant patients is less effective

	==Disposition==		==Disposition==

Moomoodoctor: /* See Also */

2024-05-02T21:21:39Z

Moomoodoctor: /* See Also */

2024-05-02T21:21:27Z

Moomoodoctor: /* Management */

2024-05-02T21:19:09Z

Management

← Older revision		Revision as of 21:19, 2 May 2024
Line 106:		Line 106:
	*[[IVIG]] 2gm/kg over 12hr		*[[IVIG]] 2gm/kg over 12hr
	**Requires inpatient monitoring for allergic reaction		**Requires inpatient monitoring for allergic reaction
	**May increase ESR as IGs are positively charged which increases RBC sedimentation		**May increase ESR as IGs are positively charged which increases RBC sedimentation[1]
	*[[Aspirin]]		*[[Aspirin]]
	**30-100mg/kg/day is often used		**30-100mg/kg/day is often used

← Older revision		Revision as of 21:21, 2 May 2024
Line 119:		Line 119:
	==See Also==		==See Also==
	*[[Pediatric fever]]		*[[Pediatric fever]]
	*[[MIS-C]		*[[MIS-C]]

	==External Links==		==External Links==

← Older revision		Revision as of 21:21, 2 May 2024
Line 119:		Line 119:
	==See Also==		==See Also==
	*[[Pediatric fever]]		*[[Pediatric fever]]
			*[[MIS-C]

	==External Links==		==External Links==